Agenus Inc. (AGEN)

Market Cap	42.01M
Revenue (ttm)	103.46M
Net Income (ttm)	-227.43M
Shares Out	25.31M
EPS (ttm)	-10.59
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	476,685
Open	1.680
Previous Close	1.670
Day's Range	1.650 - 1.765
52-Week Range	1.550 - 19.690
Beta	1.23
Analysts	Buy
Price Target	8.00 (+381.93%)
Earnings Date	Mar 11, 2025

About AGEN

Agenus Inc., a clinical-stage biotechnology company, discovers and develops therapies to activate the body's immune system against cancer and infections in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, a programmed death receptor-1 (PD-1) blocking antibody; AGEN1181, a human Fc-enhanc...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 4, 2000
• Employees: 316
• Stock Exchange: NASDAQ
• Ticker Symbol: AGEN
• Website: https://www.agenusbio.com

Financial Performance

In 2024, Agenus's revenue was $103.46 million, a decrease of -33.81% compared to the previous year's $156.31 million. Losses were -$227.43 million, -7.54% less than in 2023.

Analyst Forecast

According to 4 analysts, the average rating for AGEN stock is "Buy." The 12-month stock price forecast is $8.0, which is an increase of 381.93% from the latest price.

Price Target

$8.0

(381.93% upside)

Analyst Consensus: Buy